The weight-loss drug market is fracturing beyond Novo Nordisk and Eli Lilly as smaller pharmaceutical and biotech firms race to develop competing treatments. Companies including Viking Therapeutics, Viking Therapeutics VKTX, Structure Therapeutics, and others are advancing oral formulations and injectable alternatives designed to capture share from blockbuster semaglutide and tirzepatide products.
Viking Therapeutics released Phase 2b trial data showing VK2735 achieved average weight loss of 15% over 13 weeks at higher doses, positioning the compound as a faster-acting competitor to established GLP-1 and GLP-1/GCG dual agonists. Structure Therapeutics pursues an oral daily pill approach rather than weekly injections, targeting patient convenience and compliance. Amgen, a major pharma player with deeper pockets, also entered the fray with MariTide, a monthly injectable in late-stage development.
The competitive pressure reflects the scale of the opportunity. Global weight-loss drug sales could exceed $100 billion annually by 2030 as penetration expands beyond obesity treatment into preventive metabolic health. Novo Nordisk NVO dominates with Ozempic and Wegovy, while Eli Lilly LLY captures significant share through Mounjaro and Zepbound. Both companies face supply chain constraints that have limited availability, creating an opening for alternatives.
Smaller biotechs pursuing oral formulations address a key patient preference. Injectable fatigue and injection anxiety remain barriers to broader adoption. Daily pills offer convenience over weekly shots, though efficacy trade-offs remain unclear. Viking's data suggests oral candidates can match or approach injectable potency, which would reshape competitive dynamics.
Regulatory timelines matter. Viking expects potential approval for VK2735 in 2025 or 2026. Structure's timeline remains less defined. Amgen's MariTide could reach markets in 2025, providing another major competitor. Continued trial delays or safety signals could slow any company's progress.
Supply constraints at Novo and Lilly persist despite manufacturing ramp-up. Shortages have kept demand elevated and pricing power intact. New entrants could fragment the market if they overcome manufacturing scale challenges themselves. Insurance coverage remains restrictive, limiting paid access to weight-loss medications outside obesity diagnosis.
Investors tracking this sector should monitor Viking Therapeutics VKTX trial data releases, Novo Nordisk NVO and Eli Lilly LLY manufacturing updates, and FDA approval timelines for oral alternatives. Supply chain normalization and competitive entry will determine whether incumbents sustain premium valuations or erosion accelerates through 2025.